U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details

Renal Cell Cancer

; .

Author Information and Affiliations

Last Update: July 31, 2023.

Continuing Education Activity

Renal cell carcinomas (RCCs), which originate within the renal cortex, are responsible for 80% to 85% of all primary renal neoplasms. Transitional cell carcinomas, which originate in the renal pelvis, comprise approximately 8%. Other parenchymal epithelial tumors, such as oncocytomas, collecting duct tumors, angiomyolipomas, and renal sarcomas, occur infrequently. This activity reviews the causes, pathophysiology, presentation and diagnosis of renal cell cancers and highlights the role of the interprofessional team in the management of these patients.


  • Identify the etiology of renal cell cancer.
  • Explain the workup of a patient with renal cancer.
  • Outline the treatment and management options available for renal cell cancer
  • Review interprofessional team strategies for improving care and outcomes in patients with renal cell cancer.
Access free multiple choice questions on this topic.


Renal cell carcinomas (RCCs), which originate within the renal cortex, are responsible for 80% to 85% of all primary renal neoplasms. Transitional cell carcinomas, which originate in the renal pelvis, comprise approximately 8%. Other parenchymal epithelial tumors, such as oncocytomas, collecting duct tumors, angiomyolipomas, and renal sarcomas, occur infrequently. In children, nephroblastoma and Wilms tumor are common. Medullary renal carcinoma is a rare but aggressive form of renal cell cancer that seen in sickle cell disease. Other less common subtypes are clear cell, papillary, and chromophobe malignancies.[1][2][3]


The exact cause of RCC is unknown. The following factors increase a person's risk for renal cancer: older age, obesity, hypertension, chronic renal failure, dialysis treatment, polycystic kidney disease, African American race, sickle cell disease, and renal stones.[4][5]

The following hereditary diseases increase the risk of RCC: tuberous sclerosis, Von Hippel-Lindau syndrome  Birt-Hogg-Dube syndrome, hereditary papillary renal carcinoma, and hereditary leiomyomatosis and renal cell carcinoma (HLRCC).

Many studies have suggested that workplace exposure to certain substances increases the risk of RCC. Some of these substances are cadmium, herbicides, asbestos, and trichloroethylene.


RCC is the most common type of kidney cancer in adults. It occurs most often in men ages 50 to 70.

Globally, the incidence of RCC varies, with the highest rates observed in the Czech Republic and North America. In the United States, there are approximately 63,000 new cases and almost 14,000 deaths each year.

In the United States, incidence rates of RCC have been on the rise through the mid-2000s. Most of the increases since the 1980s occurred in early-stage tumors.[6]


The proximal renal tubular epithelium is the kidney tissue from which RCC arises. The two forms are sporadic: nonhereditary and hereditary. The structural alterations of both forms occur on the short arm of chromosome 3 (3p).

Families at high risk for developing renal cancer were studied, which led to the cloning of genes. The genes whose alteration resulted in RCC formation were tumor suppressors (VHL, TSC) or oncogenes (MET).


Subtypes of renal cell cancer include:

  • Clear cell- most common and contains a cytoplasm rich in glycogen and lipids. This subtype is likely to be associated with 3p deletion.
  • Chromophilic masses are often bilateral and be associated with trisomy 7/17
  • Chromophobic lesions have large polygonal cells but rarely have 3p deletion
  • Oncocytoma lesions have predominance of eosinophilic cells but rarely exhibit any chromosomal defects. These lesions are least likely to spread
  • Collecting duct are very aggressive, occur in young people and often present with advanced disease

History and Physical

In the early stages, when the mass is small (less than 3 centimeters), renal cell cancer is typically asymptomatic. Approximately 25% of patients are asymptomatic, and the solid renal mass is an incidental finding during a routine radiological study.

As the mass grows, symptoms may include hematuria, back pain, flank mass, fatigue, weight loss, anemia, fever, and/or high serum calcium level.

The classic clinical triad of flank pain, hematuria, and flank mass is not common, presenting in only 10% of patients. When this classic triad is present, it usually indicates advanced disease.


A urine test may show hematuria. Urine analysis may detect cancer cells in the urine. A blood test may show anemia or high serum calcium levels.[7][8]

If RCC is suspected, renal and bladder ultrasound is usually the first radiographic test. If the renal ultrasound shows a solid mass or a complex cyst with septations or nodules, the next test should be a dedicated CT scan of the kidneys, ureters, and bladder before and after IV contrast with delayed imaging of the entire abdomen and pelvis.

If the renal ultrasound is negative, but the patient has unexplained hematuria, a CT scan before and after IV contrast should be the next test as small solid renal masses can be easily missed on ultrasound and small renal stones also can be missed on ultrasound.

On CT scan, RCC will typically demonstrate significant enhancement; usually, greater than 20 Hounsfield units (HU), more after contrast. Typically, postcontrast HU of renal cancer measure about 141 HU. The subtypes papillary cell and clear cell may enhance less than RCC.

CT scan is used to stage RCC. CT scan will detect lymphadenopathy and invasion to the renal vein or inferior vena cava or invasion to adjacent organs. CT scan can detect metastatic disease to the bones of the abdomen and pelvis only. Whole body bone scan is the test of choice to detect bone metastases. Chest CT scan also should be obtained, as RCC presents with lung metastases in about 10% to 20%. The use of PET-CT is controversial but is helpful for distant metastases.

Abdominal MRI is just as good as CT scan for diagnosing and staging RCC but is more subject to limitations such as respiratory motion artifact because the images take longer to acquire.

Treatment / Management

Treatment depends on the stage of the tumor. See staging."

  • For stage I renal cell cancer measuring less than 7 centimeters and confined to the kidney, nephrectomy or partial nephrectomy is the treatment of choice and is usually curative. Radiofrequency ablation or cryotherapy is an option in patients with bilateral tumors and small cortical tumors. Imaging surveillance is an option in elderly patients with a short life expectancy who are not good surgical candidates, as many renal cell cancers are slow growing.
  • For stage II renal cell cancer, laparoscopic radical nephrectomy is the treatment of choice.
  • For stage III renal cell cancer, open radical nephrectomy is the standard of care. Adrenalectomy or extensive lymph node dissection is only recommended when abdominal CT shows evidence of adrenal or lymph node invasion.
  • Stage IV renal cell cancer is not curable. Treatment is palliative. Treatment may include tumor embolization, external-beam radiation therapy, and nephrectomy, but these treatments are not aimed at cure, rather prolonged survival and palliation. Immunotherapy and chemotherapy can prolong survival. Drugs that may be used to reduce the risk of complications from bone metastases include bisphosphonates and Xgeva.[9][10]

Differential Diagnosis

The differential diagnosis of other solid renal tumors includes the following: renal oncocytoma, lipid-poor renal angiomyolipoma, renal metastases, renal lymphoma, solitary fibrous tumor (very rare), and multilocular cystic nephroma.

Other renal abnormalities that can mimic RCC include the following: a prominent column of Bertin, renal abscess, renal infarct, and complex renal cyst. 

The finding of a prominent column of Bertin is typically a questionable ultrasound finding which requires cross-sectional imaging CT scan or MRI to confirm. 

The finding of renal access typically has other clinical findings to support such as pyelonephritis, high white blood cell (WBC) count, fever, and chills.

The finding of renal infarct is usually associated with vascular abnormalities such as renal vein thrombosis or trauma related.

To differentiate a complex renal cyst from renal cell cancer, radiologists use the Bosniak classification.


Below is the Robson staging for RCC; although it has largely been replaced by the TNM staging which is much more complicated.

Robson staging:

  • Stage I: limited to kidney
  • Stage II: involvement of perinephric fat but remains limited to Gerota's fascia
  • Stage III
  • IIIa: renal vein involvement
  • IIIb: nodal involvement
  • IIIc: both IIIa and IIIb
  • Stage IV
  • IVa: direct invasion of adjacent organs/structures
  • IVb: distant metastases

TNM staging (seventh edition)

  • T1
  • T1a: limited to kidney, greater than 4 cm
  • T1b: limited to kidney, greater than 4 cm but less than 7 cm
  • T2: limited to kidney, greater than 7 cm
  • T2a: limited to kidney, greater than 7 cm but not more than 10 cm
  • T2b: limited to kidney, greater than 10 cm
  • T3: tumor/tumor thrombus extension into major veins or perinephric tissues but not into ipsilateral adrenal gland or beyond the Gerota fascia
  • T3a: spread to renal vein
  • T3b: spread to infra-diaphragmatic IVC
  • T3c: spread to supradiaphragmatic IVC or invades the wall of the IVC
  • T4: involves ipsilateral adrenal gland or invades beyond Gerota's fascia
  • N0: no nodal involvement
  • N1: metastatic involvement of regional lymph node/sM
  • M0: no distant metastases
  • M1: distant metastasesStage groupings
  • Stage I: T1 N0 M0
  • Stage II: T2 N0 M0
  • Stage III: T3 or N1 with M0
  • Stage IV: T4 or M1


The prognosis depends on stage on histology of the cell type.

  • Stage 1 has a 90% 5-year survival rate.
  • Stage 2 has a 50% 5-year survival rate.
  • Stage 3 gas a 30 % 5-year survival rate.
  • Sagte 4 has a 5% 5-year survival rate.

Papillary RCC has the best 5-year survival rate, 90%. Clear cell cancer subtype has second-best 5-year survival, 70%.

Enhancing Healthcare Team Outcomes

Evidence-based approach to renal cell cancer

Renal cell cancer is relatively common in the US and often presents with nonspecific signs and symptoms. The malignancy is ideally managed with an interprofessional team that includes a urologist, nephrologist, oncologist, and a geneticist. Over the past two decades, the mortality rates from this malignancy have dropped because of earlier detection and treatment. five-year survival for stage 1 cancer is greater than 90% and 79% for stage 2 renal cancer. For those with lymph node involvement, the survival drops to less than 40% over five years. Factors associated with improved survival include obesity, good performance status, complete excision of the primary and a long disease-free interval from the time of surgery to the presence of metastases. Patients with a family history should be educated about the need for other members of the family to undergo screening. Patients at high risk for renal cell cancer should also be educated about the signs and symptoms; as earlier the cancer is managed, the better the prognosis.[11][12] (Level V)

Review Questions



Abdomen CT, Bosniak IV Left Renal Cell Lesion Consistent With Renal Cell Carcinoma Contributed by Scott Dulebohn, MD

Histology, Pathology, Histopathology of renal cell adenocarcinoma kidney, Cancer, Neoplasms, Kidney Diseases Contributed by Dr


Histology, Pathology, Histopathology of renal cell adenocarcinoma kidney, Cancer, Neoplasms, Kidney Diseases Contributed by Dr. Edwin P. Ewing Jr., The Centers for Disease Control and Prevention (CDC)

Gross Pathology of Bisected Kidney, Large Renal Cell Carcinoma, Tumor tissu, Renal cortex, Neoplasms Contributed by Dr


Gross Pathology of Bisected Kidney, Large Renal Cell Carcinoma, Tumor tissu, Renal cortex, Neoplasms Contributed by Dr. Edwin P. Ewing Jr., The Centers for Disease Control and Prevention (CDC)


Kuroda N, Sugawara E, Kusano H, Yuba Y, Yorita K, Takeuchi K. A review of ALK-rearranged renal cell carcinomas with a focus on clinical and pathobiological aspects. Pol J Pathol. 2018;69(2):109-113. [PubMed: 30351856]
Grünwald V. [Risk-adapted (immuno)therapy for renal cell carcinoma]. Urologe A. 2018 Nov;57(11):1326-1333. [PubMed: 30350129]
Ding M, Lu X, Wang C, Zhao Q, Ge J, Xia Q, Wang J, Zen K, Zhang CY, Zhang C. The E2F1-miR-520/372/373-SPOP Axis Modulates Progression of Renal Carcinoma. Cancer Res. 2018 Dec 15;78(24):6771-6784. [PubMed: 30348808]
van Leeuwaarde RS, Ahmad S, van Nesselrooij B, Zandee W, Giles RH. Von Hippel-Lindau Syndrome. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. University of Washington, Seattle; Seattle (WA): May 17, 2000. [PubMed: 20301636]
Ganguly S, Chandra A, Chatterjee IB. Pathobiology of cigarette smoke-induced invasive cancer of the renal pelvis and its prevention by vitamin C. Toxicol Rep. 2018;5:1002-1010. [PMC free article: PMC6186955] [PubMed: 30338226]
Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, Gore JL, Sun M, Wood C, Russo P. Epidemiology of Renal Cell Carcinoma. Eur Urol. 2019 Jan;75(1):74-84. [PMC free article: PMC8397918] [PubMed: 30243799]
Ward RD, Tanaka H, Campbell SC, Remer EM. 2017 AUA Renal Mass and Localized Renal Cancer Guidelines: Imaging Implications. Radiographics. 2018 Nov-Dec;38(7):2021-2033. [PubMed: 30339517]
Liaw CW, Winoker JS, Mehrazin R. Imaging Protocols for Active Surveillance in Renal Cell Carcinoma. Curr Urol Rep. 2018 Aug 13;19(10):81. [PubMed: 30105557]
Jonasch E. Updates to the Management of Kidney Cancer. J Natl Compr Canc Netw. 2018 May;16(5S):639-641. [PubMed: 29784745]
Dabestani S, Marconi L, Kuusk T, Bex A. Follow-up after curative treatment of localised renal cell carcinoma. World J Urol. 2018 Dec;36(12):1953-1959. [PubMed: 29767327]
Rolley C, Aubert C, Baize N, Bigot P. [Management of metastatic renal cell carcinomass]. Prog Urol. 2018 Nov;28(14):777-782. [PubMed: 30174169]
Joshi SS, Handorf EA, Zibelman M, Plimack ER, Uzzo RG, Kutikov A, Smaldone MC, Geynisman DM. Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis. Eur Urol. 2018 Sep;74(3):387-393. [PMC free article: PMC7548437] [PubMed: 29880274]

Disclosure: Karen Garfield declares no relevant financial relationships with ineligible companies.

Disclosure: Chad LaGrange declares no relevant financial relationships with ineligible companies.

Copyright © 2024, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

Bookshelf ID: NBK470336PMID: 29261992


  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...